Ensysce Biosciences (NASDAQ: ENSC) reported a net loss of $2.6 million, or $0.20 per basic and diluted share, for the second quarter ended June 30, 2026. Federal grant funding totaled $1.2 million, while research and development expenses were $2.5 million.
The company completed its acquisition of Cy Biopharma on August 6, adding CY200, an Orphan Drug-designated candidate for complex regional pain syndrome. The transaction and related financings provided approximately $31 million in cash net of transaction expenses, according to the release.
- Cash and cash equivalents were $0.7 million at June 30, 2026, compared with $4.3 million at December 31, 2025.
- Cy Biopharma acquisition included $38.6 million in private-placement financings, with a potential second tranche of up to $38.6 million tied to clinical milestones.
- R&D expense rose to $2.5 million from $1.9 million a year earlier; G&A expense was $1.3 million.
- Ensysce said $5.3 million remained available through May 2027 under its NIDA grant as of June 30, 2026.
- The company will host a corporate update call on August 18, 2026, at 11:00 a.m. ET.
